Skip to main content

Cost-effective reimbursement analysis for medical technologies in Europe

Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 20 EU countries

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Ongoing health technology assessments in Scotland in August 2025

The Scottish Health Technologies Group (SHTG) is a national health technology assessment (HTA) body within Healthcare Improvement Scotland. Its primary role is to offer evidence-based advice to NHS Scotland on the use of non-medicine health technologies, such as devices, diagnostics, digital tools, and procedures, to inform safe, cost-effective, and equitable care decisions across Scotland.

As of August 2025, the SHTG is developing four HTAs in cardiovascular, diagnostic imaging, neurology and neurosurgery, neuromodulation, and orthopedics areas. 

The examples of technologies under evaluation include:

  • Optune Gio® Tumour-Treating Field Therapy;
  • Home blood pressure monitoring;
  • Esaote extremity MRI scanners.

See the full details in English here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.